{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:23:08Z","timestamp":1787761388726,"version":"build-2784847793"},"reference-count":27,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,9,18]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase III studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assess the impact of BKZ on peripheral manifestations to week 104 of those studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BE MOBILE 1 (nr-axSpA) and 2 (r-axSpA) each comprised a 16-week double-blind, placebo-controlled period, then all received BKZ 160 mg every 4 weeks for 36 weeks. Patients not meeting withdrawal criteria could enter a combined open-label extension. We report change in enthesitis (Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)) in patients with baseline MASES&gt;0, peripheral arthritis (swollen joint count (SJC)\/Disease Activity Index for Psoriatic Arthritis (DAPSA)) in patients with baseline SJC&gt;0\u2009and proportions achieving DAPSA disease states to week 104. Resolution of enthesitis (MASES=0)\/arthritis (SJC=0) is reported to week 104 for those with baseline enthesitis\/arthritis. We also report associations between peripheral manifestation resolution (MASES=0\/SJC=0) and week 104 clinical outcomes in those with baseline enthesitis\/arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 186\/254 (73.2%) and 88\/254 (34.6%) patients with nr-axSpA had enthesitis (MASES&gt;0) and arthritis (SJC&gt;0), respectively, compared with 199\/332 (59.9%) and 66\/332 (19.9%) patients with r-axSpA. Pooled BKZ\/placebo-randomised patients with enthesitis (nr-axSpA\/r-axSpA) showed average MASES improvement from 4.8\/4.3 (baseline) to 1.6\/1.3 (week 52) and 1.6\/1.0 (week 104). Pooled BKZ\/placebo-randomised patients with arthritis showed average SJC improvement from 4.0\/4.5 (baseline) to 1.2\/0.7 (week 52) and 0.9\/0.6 (week 104). Over 60% of patients achieved DAPSA low disease activity\/remission by week 52. Over 40%\/60% patients achieved resolution of enthesitis (MASES=0)\/arthritis (SJC=0) at week 104; enthesitis resolution was associated with larger improvements in week 104 clinical outcomes for patients with r-axSpA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BKZ resulted in sustained improvements in peripheral manifestations to 2 years across the full disease spectrum of axSpA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005969","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:50:13Z","timestamp":1761123013000},"page":"e005969","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands"},{"name":"Zuyderland Medical Center, Heerlen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Gastroenterology, Infectious Diseases and Rheumatology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Swedish Medical Center\/Providence St. Joseph Health and University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-5837","authenticated-orcid":false,"given":"Clementina","family":"L\u00f3pez-Medina","sequence":"additional","affiliation":[{"name":"Reina Sofia University Hospital, IMIBIC and University of Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Kim","sequence":"additional","affiliation":[{"name":"UCB, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[{"name":"UCB, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB, Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-397X","authenticated-orcid":false,"given":"Tue Wenzel","family":"Kragstrup","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, Aarhus, Denmark"},{"name":"Rheumatology Section, Medical Diagnostic Center, Regional Hospital Silkeborg, Silkeborg, Denmark"},{"name":"Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-8226","authenticated-orcid":false,"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Academic Unit for the Musculoskeletal Diseases, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026010700551752000_11.4.e005969.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2026010700551752000_11.4.e005969.2","doi-asserted-by":"crossref","unstructured":"L\u00f3pez Medina C , Molt\u00f3 A , Capelusnik D , et al . Impact of peripheral manifestations on function, health, and work productivity in patients with axial spondyloarthritis, peripheral spondyloarthritis and psoriatic arthritis. Data from the ASAS-PerSpA Study. ACR Convergence, 2024.","DOI":"10.1136\/annrheumdis-2024-eular.5507"},{"key":"2026010700551752000_11.4.e005969.3","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Medina C , Molt\u00f3 A , Sieper J , et al . Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open 2021;7. doi:10.1136\/rmdopen-2020-001450","DOI":"10.1136\/rmdopen-2020-001450"},{"key":"2026010700551752000_11.4.e005969.4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026010700551752000_11.4.e005969.5","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s10067-019-04514-4","article-title":"Are extra-spinal symptoms associated with quality of life in patients with axial spondyloarthritis? A 1-year follow-up study","volume":"38","author":"Kwan","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2026010700551752000_11.4.e005969.6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2021.04.007","article-title":"Peripheral arthritis and higher disease activity lead to more functional impairment in axial spondyloarthritis: longitudinal analysis from ESPAXIA","volume":"51","author":"Capelusnik","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026010700551752000_11.4.e005969.7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.semarthrit.2021.07.011","article-title":"Hidden in plain sight: Is there a crucial role for enthesitis assessment in the treatment and monitoring of axial spondyloarthritis?","volume":"51","author":"McGonagle","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026010700551752000_11.4.e005969.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188"},{"key":"2026010700551752000_11.4.e005969.9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-019-1927-6","article-title":"Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort","volume":"21","author":"L\u00f3pez-Medina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026010700551752000_11.4.e005969.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224959"},{"key":"2026010700551752000_11.4.e005969.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2026010700551752000_11.4.e005969.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.021"},{"key":"2026010700551752000_11.4.e005969.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2026010700551752000_11.4.e005969.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"2026010700551752000_11.4.e005969.15","doi-asserted-by":"crossref","unstructured":"Deodhar A , Navarro-Comp\u00e1n V , Poddubnyy D , et al . Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open 2025;11. doi:10.1136\/rmdopen-2024-005081","DOI":"10.1136\/rmdopen-2024-005081"},{"key":"2026010700551752000_11.4.e005969.16","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","article-title":"Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies","volume":"64","author":"Baraliakos","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026010700551752000_11.4.e005969.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2026010700551752000_11.4.e005969.18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ard.2025.02.011","article-title":"Evaluation of instruments assessing peripheral arthritis in spondyloarthritis: an analysis of the ASAS-PerSpA study","volume":"84","author":"Capelusnik","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026010700551752000_11.4.e005969.19","doi-asserted-by":"crossref","unstructured":"Capelusnik D , L\u00f3pez-Medina C , van der Heijde D , et al . POS0910 Development and Validation of a Disease Activity Index for Psoriatic Arthritis Based on 44 Joints: DAPSA44. EULAR, 2025.","DOI":"10.1016\/j.ard.2025.08.027"},{"key":"2026010700551752000_11.4.e005969.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224803"},{"key":"2026010700551752000_11.4.e005969.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181331"},{"key":"2026010700551752000_11.4.e005969.22","doi-asserted-by":"crossref","unstructured":"Mac Gearailt C , O\u2019shea F , Fitzgerald G . POS0433 The Association Between Depression and Biologic Prescribing in Axial Spondyloarthritis (axSpA): Lessons From an Irish axSpA Cohort. EULAR, 2024.","DOI":"10.1136\/annrheumdis-2024-eular.6220"},{"key":"2026010700551752000_11.4.e005969.23","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00296-024-05707-0","article-title":"Distinct clinical outcomes linked to peripheral arthritis and dactylitis in axial spondyloarthritis: findings from a retrospective Irish cohort","volume":"44","author":"Kenyon","year":"2024","journal-title":"Rheumatol Int"},{"key":"2026010700551752000_11.4.e005969.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191117"},{"key":"2026010700551752000_11.4.e005969.25","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","article-title":"Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial","volume":"61","author":"Behrens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026010700551752000_11.4.e005969.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201111"},{"key":"2026010700551752000_11.4.e005969.27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/annrheumdis-2023-eular.831","article-title":"POS0247 Resolution of enthesitis and peripheral arthritis with bimekizumab in patients with axial spondyloarthritis: week 52 results from the BE MOBILE 1 and BE MOBILE 2 phase 3 studies","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:55:28Z","timestamp":1767776128000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-005969"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005969","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}